Drug intelligence / Profile preview

Aponia Pain Gel

Development stage: Preclinical
Lead developer: Aponia Laboratories
Modality: Small Molecules
Administration: Topical

Overview

Aponia Pain Gel is a topical formulation of the nonsteroidal anti-inflammatory drug (NSAID) ibuprofen, developed by Aponia Laboratories. It is intended for the localized treatment of arthritis-related pain and general musculoskeletal pain. The drug functions by inhibiting the cyclooxygenase enzymes COX-1 and COX-2, which prevents the synthesis of prostaglandins that mediate pain, fever, and inflammation. According to the developer's pipeline, the product has completed formulation development and non-clinical studies and is proceeding toward clinical trials under FDA guidance.

Brand names: Aponia Pain Gel
Other names: ibuprofen-based topical NSAID gel

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on Aponia Pain Gel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aponia Pain Gel.

Explore the full profile